<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02191007</url>
  </required_header>
  <id_info>
    <org_study_id>CUP2012D001</org_study_id>
    <nct_id>NCT02191007</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Calcipotriol Betamethasone Plus Calcipotriol in Sequential Therapy to Psoriasis</brief_title>
  <official_title>Multi-center,Single Blind, Parallel-Controlled Study of the Efficacy and Safety of Calcipotriol Betamethasone Ointment Plus Calcipotriol Ointment in Sequential Therapy to Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <brief_summary>
    <textblock>
      Evaluate the efficacy and safety of Calcipotriol Betamethasone Ointment and Calcipotriol
      Ointment in sequential therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1.240 subjects will be randomized 1:1:1 divided into the 3 groups 2.Week0 to Week4,each group
      were treated with Calcipotriol Betamethasone Ointment 3.Week4 to Week12, the there group were
      respectively treated with Calcipotriol Betamethasone Ointment,Calcipotriol Ointment and Urea
      Cream 4.The efficacy and safety were evaluated at the baseline, as well as 1, 4, 8 and 12
      weeks after the beginning of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psoriasis Area and Severity Index 50 ,75 and 90</measure>
    <time_frame>week0 and week12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>Any Point In Time after 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Calcipotriol/Betamethasone and Calcipotriol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcipotriol/Betamethasone ointment 1/d for 4 weeks; Calcipotriol ointment bid for 6 weeks on-demand treatment period;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcipotriol/Betamethasone and urea cream</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>alcipotriol/Betamethasone ointment 1/d for 4 weeks , urea cream 1/d for 6 weeks on-demand treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcipotriol/Betamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcipotriol/Betamethasone ointment 1/d for 4 weeks, Calcipotriol/Betamethasone ointment 1/d for 6 weeks on-demand treatment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriol Betamethasone ointment and Calcipotriol ointment</intervention_name>
    <arm_group_label>Calcipotriol/Betamethasone and Calcipotriol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriol Betamethasone ointment</intervention_name>
    <arm_group_label>Calcipotriol/Betamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriol Betamethasone ointment and Urea Cream</intervention_name>
    <arm_group_label>Calcipotriol/Betamethasone and urea cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who signed Informed Consent Form；

          2. Male or female subjects 18-65 years of age；

          3. Clinically confirmed diagnosis of plaque psoriasis as per the diagnostic criteria for
             psoriasis vulgaris specified in Clinical Dermatology.

          4. Involved area 1-10% of the body surface area.

        Exclusion Criteria:

          1. Incompliance with the diagnosis of plaque psoriasis or plaque area &gt; 10% of the body
             surface area.

          2. Erythrodermic psoriasis, psoriasis arfhropathica or pustular psoriasis;

          3. Known allergy to any component of the test or control drug；

          4. Concomitant allergic skin disease such as eczema， contact dermatitis and urticaria, or
             other serious and/or extensive skin disease；

          5. Systemic medication or ultraviolet therapy for psoriasis within 4 weeks prior to study
             initiation；

          6. Topical use of external drug for psoriasis within 2 weeks prior to study initiation；

          7. Women of child-bearing potential who are pregnant, plan to become pregnant during
             study or are lactating；

          8. Glucocorticoid or immunodepressant, or hypoleukemia due to tumor or chemotherapy
             within the last 4 weeks；

          9. Serious life-threatening condition that allows a life expectancy of less than 2
             months；

         10. Inability to guarantee taking medications and completing visits as scheduled during
             the study;

         11. Serious infection that is not suitable for external treatment；

         12. Any other condition that the investigator deems unsuitable for entering the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2013</study_first_submitted>
  <study_first_submitted_qc>July 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2014</study_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital</investigator_affiliation>
    <investigator_full_name>xjpfW</investigator_full_name>
    <investigator_title>Wang Gang</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

